Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
ConditionMultiple Myeloma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorNanjing IASO Biotechnology Co., Ltd.
About this trial
This is a multicenter, open-label, single-arm, long-term follow-up clinical study. All patients who have received Equecabtagene Autoleucel Injection treatment will be enrolled.
Eligibility criteria
Qualifiers
None
Disqualifiers
1. Receipt of another lentiviral vector-based cell or gene therapy (either commercialized product or investigational product in a clinical tiral) between the infution of Equecabtagene Autoleucel Injection and the signing informed consent.
Trial design
Treatments tested in this trial
- No Intervention (subjects were previously treated with Equecabtagene Autoleucel Injection) )
Treatment groups
1,500 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov